

Title (en)  
MONOCLONAL ANTIBODIES AGAINST THE RGM A PROTEIN AND USES THEREOF

Title (de)  
MONOKLONALE ANTIKÖRPER GEGEN DAS RGM-A-PROTEIN UND VERWENDUNGEN DAVON

Title (fr)  
ANTICORPS MONOCLONAUX CONTRE LA PROTÉINE RGM A ET SES UTILISATIONS

Publication  
**EP 2995625 A1 20160316 (EN)**

Application  
**EP 15177075 A 20090227**

Priority

- US 3270708 P 20080229
- US 9074308 P 20080821
- EP 09715176 A 20090227

Abstract (en)

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but not limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.

IPC 8 full level  
**C07K 16/22** (2006.01); **A61K 39/00** (2006.01); **A61K 39/395** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EP KR US)

**A61K 39/395** (2013.01 - KR); **A61K 39/39533** (2013.01 - KR); **A61K 39/3955** (2013.01 - US); **A61K 45/06** (2013.01 - US); **A61P 7/04** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 21/04** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/02** (2017.12 - EP); **A61P 25/14** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/20** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/06** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 16/22** (2013.01 - EP KR US); **C07K 16/28** (2013.01 - KR US); **C12N 15/1138** (2013.01 - KR); **A61K 2039/505** (2013.01 - EP US); **C07K 2317/24** (2013.01 - EP US); **C07K 2317/56** (2013.01 - EP US); **C07K 2317/565** (2013.01 - EP US); **C07K 2317/567** (2013.01 - US); **C07K 2317/76** (2013.01 - EP US); **C07K 2317/92** (2013.01 - EP US); **Y02A 50/30** (2017.12 - EP US)

Citation (search report)

- [Y] WO 2007062852 A2 20070607 - ABBOTT LAB [US], et al
- [Y] HATA KATSUHIKO ET AL: "RGMa inhibition promotes axonal growth and recovery after spinal cord injury.", THE JOURNAL OF CELL BIOLOGY 10 APR 2006, vol. 173, no. 1, 10 April 2006 (2006-04-10), pages 47 - 58, XP002529131, ISSN: 0021-9525
- [Y] KYOTO ET AL: "Synapse formation of the cortico-spinal axons is enhanced by RGMa inhibition after spinal cord injury", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1186, 23 October 2007 (2007-10-23), pages 74 - 86, XP022374699, ISSN: 0006-8993
- [A] RAJAGOPALAN SRIKANTH ET AL: "Neogenin mediates the action of repulsive guidance molecule", NATURE CELL BIOLOGY, NATURE PUBLISHING GROUP, GB, vol. 6, no. 8, 1 August 2004 (2004-08-01), pages 756 - 762, XP002424999, ISSN: 1465-7392
- [A] HAREL NOAM Y ET AL: "Can regenerating axons recapitulate developmental guidance during recovery from spinal cord injury?", NATURE REVIEWS NEUROSCIENCE, vol. 7, no. 8, August 2006 (2006-08-01), pages 603 - 616, XP002529132, ISSN: 1471-0048
- [A] LAURA MARIE CAMUS ET AL: "Molecular Evolution of Hemojuvelin and the Repulsive Guidance Molecule Family", JOURNAL OF MOLECULAR EVOLUTION, SPRINGER-VERLAG, NE, vol. 65, no. 1, 25 June 2007 (2007-06-25), pages 68 - 81, XP019538398, ISSN: 1432-1432
- [AP] SCHAFFAR GREGOR ET AL: "LIM-only protein 4 interacts directly with the repulsive guidance molecule A receptor Neogenin", JOURNAL OF NEUROCHEMISTRY, vol. 107, no. 2, October 2008 (2008-10-01), pages 418 - 431, XP002529133, ISSN: 0022-3042
- [IP] SUDA M ET AL: "Peptides derived from repulsive guidance molecule act as antagonists", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 371, no. 3, 4 July 2008 (2008-07-04), pages 501 - 504, XP022670730, ISSN: 0006-291X, [retrieved on 20080429]

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

Designated extension state (EPC)  
AL BA RS

DOCDB simple family (publication)

**WO 2009106356 A1 20090903**; AR 070709 A1 20100428; AU 2009218693 A1 20090903; AU 2009218693 B2 20141023; BR 122012004341 A2 20150714; BR 122012004341 B1 20220315; BR P10908012 A2 20141014; CA 2715456 A1 20090903; CA 2715456 C 20201027; CA 3090849 A1 20090903; CL 2009000459 A1 20101210; CL 2013003244 A1 20140509; CO 6311003 A2 20110822; CR 11691 A 20110103; CR 20170015 A 20170417; DK 2260055 T3 20151109; DO P2010000258 A 20100915; DO P2013000081 A 20140415; EC SP10010481 A 20101030; EP 2260055 A1 20101215; EP 2260055 B1 20150729; EP 2995625 A1 20160316; EP 2995625 B1 20171129; EP 3309173 A1 20180418; ES 2549959 T3 20151103; GT 201000249A A 20140520; HK 1145846 A1 20110506; HK 1254184 A1 20190712; IL 207787 A0 20101230; IL 207787 A 20160331; IL 226343 A0 20130627; JP 2011512806 A 20110428; JP 2014138599 A 20140731; JP 2016175897 A 20161006; JP 2018021041 A 20180208; JP 2020018316 A 20200206; JP 2022036944 A 20220308; JP 2023103237 A 20230726; JP 5661474 B2 20150128; JP 5986123 B2 20160906; KR 101681910 B1 20161205; KR 20100118606 A 20101105; KR 20160091457 A 20160802; MX 2010009505 A 20110304; MY 159596 A 20170113; NZ 587198 A 20121026; NZ 602256 A 20140328; PE 20091474 A1 20091028; PE 20140848 A1 20140815; PH 12013502068 A1 20150126; PL 2260055 T3 20160129; PT 2260055 E 20151104; RU 2010139886 A 20120410; RU 2013123720 A 20141127; RU 2524136 C2 20140727; SG 10201607301X A 20161028; TW 201002344 A 20100116; TW 201545760 A 20151216; TW I508741 B 20151121; US 2010028340 A1 20100204; US 2015183871 A1 20150702; US 2017166633 A1 20170615; US 2018162933 A1 20180614; US 2021230260 A1 20210729; US 8962803 B2 20150224; US 9605069 B2 20170328; UY 31677 A1 20090930; ZA 201208539 B 20150429

DOCDB simple family (application)

**EP 2009001437 W 20090227**; AR P090100700 A 20090227; AU 2009218693 A 20090227; BR 122012004341 A 20090227; BR P10908012 A 20090227; CA 2715456 A 20090227; CA 3090849 A 20090227; CL 2009000459 A 20090227; CL 2013003244 A 20131112; CO 10117825 A 20100923; CR 11691 A 20100927; CR 20170015 A 20090227; DK 09715176 T 20090227; DO 2010000258 A 20100824; DO 2013000081 A 20130412; EC SP10010481 A 20100913; EP 09715176 A 20090227; EP 15177075 A 20090227; EP 17204022 A 20090227;

ES 09715176 T 20090227; GT 201000249 K 20121217; HK 11100081 A 20110106; HK 18113321 A 20181018; IL 20778710 A 20100824;  
IL 22634313 A 20130513; JP 2010548035 A 20090227; JP 2014032545 A 20140224; JP 2016051959 A 20160316; JP 2017151514 A 20170804;  
JP 2019182721 A 20191003; JP 2021180878 A 20211105; JP 2023066952 A 20230417; KR 20107021295 A 20090227;  
KR 20167020260 A 20090227; MX 2010009505 A 20090227; MY PI2010003873 A 20090227; NZ 58719809 A 20090227;  
NZ 60225609 A 20090227; PE 2009000315 A 20090227; PE 2013001715 A 20090227; PH 12013502068 A 20131004; PL 09715176 T 20090227;  
PT 09715176 T 20090227; RU 2010139886 A 20090227; RU 2013123720 A 20130523; SG 10201607301X A 20090227;  
TW 104130646 A 20090227; TW 98106619 A 20090227; US 201514591445 A 20150107; US 201615389627 A 20161223;  
US 201715832177 A 20171205; US 202017015442 A 20200909; US 38992709 A 20090220; UY 31677 A 20090226; ZA 201208539 A 20121113